Skip to Main Content

Paper Details

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.
Annals of the Rheumatic Diseases
198
2015
A3921024, A3921073, B cells, CCL2, CXCL10, CXCL13, JAK, JAK1, Janus kinase, MMP-3, Patients, RA, Rheumatism, STAT, STAT1, STAT3, T cells, Tofacitinib, interferon, interleukin-6, macrophages, matrix metalloproteinase (MMP)-1, metalloproteinase, methotrexate, patients, rheumatoid arthritis, rheumatoid synovium, signal transducer and activator of transcription 1, synovial inflammation, synovial mRNA, tofacitinib
Author NameAffiliation
David L BoyleUniversity of California, San Diego School of Medicine
Gary S FiresteinUniversity of California, San Diego School of Medicine
  • 1 - 2

Datasets

Release 1.2